USC 2021 Discussion: Optimal Antiplatelet Regimen in High Bleeding Risk

Published: 08 Jun 2021

  • Views:

    Views Icon 663
  • Likes:

    Heart Icon 1
Average (ratings)
No ratings
Your rating

Dr Mirvat Alasnag (The King Fahd Armed Forces Hospital, Jeddah, SA), Editor of US Cardiology Review joined by Dr Khaled Al-Shaibi (The King Fahd Armed Forces Hospital, Jeddah, SA), Dr Róisín Colleran (Mater Private Hospital & Cardiovascular Research Institute Dublin, Dublin, IR) and Dr Marco Valgimigli (Cardiocentro Ticino Institute, Lugano, CH) to discuss revascularization in high bleeding risk individuals. 
Dr Colleran shares the current definition and critical criteria of high-bleeding risk. Dr Al-Shaibi talks about variability in antiplatelet regimens in practice. Dr Valgimigli summarises the current body of evidence guiding practice. They discuss de-escalation therapy versus discontinuation of aspirin and studies that can help provide more robust evidence. 

Recorded remotely from Jeddah, Dublin, and Lugano, 2021. 

Editor: Mirjam Boros

Videography:Mike Knight